Beqvez

CareFirst Prior Authorization Request

CVS Caremark administers the prescription benefit plan for the patient identified. This patient's benefit plan requires prior authorization for certain medications in order for the drug to be covered. To make an appropriate determination, providing the most accurate diagnosis for the use of the prescribed medication is necessary. **Please respond below and fax this form to CVS Caremark toll-free at 1-855-330-1720**. If you have questions regarding the prior authorization, please contact CVS Caremark at **1-888-877-0518.** For inquiries or questions related to the patient's eligibility, drug copay or medication delivery; please contact the Specialty Customer Care Team: CaremarkConnect® 1-800-237-2767.

The recipient of this fax may make a request to opt-out of receiving telemarketing fax transmissions from CVS Caremark. There are numerous ways you may opt-out: The recipient may call the toll-free number at 877-265-2711, at any time, 24 hours a day/7 days a week. The recipient may also send an opt-out request via email to do_not_call@cvscaremark.com. An opt out request is only valid if it (1) identifies the number to which the request relates, and (2) if the person/entity making the request does not, subsequent to the request, provide express invitation or permission to CVS Caremark to send facsimile advertisements to such person/entity at that particular number. CVS Caremark is required by law to honor an opt-out request within thirty days of receipt.

Patient's Name: _____ **Date**: _____
Patient's ID: _____ **Patient's Date of Birth:** _____
Physician's Name: _____
Specialty: _____ **NPI#:** _____
Physician Office Telephone: _____ **Physician Office Fax:** _____

Referring Provider Info: ❑ **Same as Requesting Provider**
Name: _____ **NPI#:** _____
Fax: _____ **Phone:** _____

Rendering Provider Info: ❑ **Same as Referring Provider** ❑ **Same as Requesting Provider**
Name: _____ **NPI#:** _____
Fax: _____ **Phone:** _____

Approvals may be subject to dosing limits in accordance with FDA-approved labeling, accepted compendia, and/or evidence-based practice guidelines.

Required Demographic Information:

Patient Weight: _____*kg*

Patient Height: _____*cm*

Please indicate the place of service for the requested drug:

❑ *Ambulatory Surgical*	❑ *Home*	❑ *Off Campus Outpatient Hospital*
❑ *On Campus Outpatient Hospital*	❑ *Office*	❑ *Pharmacy*

What is the ICD-10 code? _____

Send completed form to: Case Review Unit CVS Caremark Specialty Programs Fax: 1-855-330-1720

 Beqvez SGM 6486-A – 06/2025.

Criteria Questions:

1. What is the diagnosis?
❒ Hemophilia B (congenital factor IX deficiency), *Continue to 2*
❒ Other, please specify. _____ *Continue to 2*

2. Is the patient 18 years of age or older?
❒ Yes, *Continue to 3*
❒ No, *Continue to 3*

3. Will the requested medication be prescribed by or in consultation with a hematologist?
❒ Yes, *Continue to 4*
❒ No, *Continue to 4*

4. Does the patient have a history of Factor IX inhibitors (greater than or equal to 0.6 Bethesda units [BU])? ***ACTION REQUIRED***: If No, please attach supporting documentation of absence of Factor IX inhibitors.
❒ Yes, *Continue to 5*
❒ No, *Continue to 5*

5. Does the patient have a negative Factor IX inhibitor test result within the past 30 days (less than 0.6 Bethesda units [BU])? ***ACTION REQUIRED***: If Yes, please attach lab test results documenting the absence of Factor IX inhibitors.
❒ Yes, *Continue to 6*
❒ No, *Continue to 6*

6. Does the patient have severe or moderately severe Factor IX deficiency (less than or equal to 2% of normal circulating Factor IX)? ***ACTION REQUIRED***: If Yes, please attach chart notes or lab tests documenting severe or moderately severe Factor IX deficiency (less than or equal to 2% of normal circulating Factor IX).
❒ Yes, *Continue to 7*
❒ No, *Continue to 7*

7. Does the patient have a history of prophylactic Factor IX (e.g., Alprolix, Ixinity, Rebinyn) use for at least 50 exposure days? ***ACTION REQUIRED***: If Yes, please attach chart notes of current use of Factor IX prophylaxis therapy.
❒ Yes, *Continue to 8*
❒ No, *Continue to 8*

8. Does the patient have uncontrolled disease while currently using Factor IX prophylactic therapy?
❒ Yes, *Continue to 10*
❒ No, *Continue to 9*

9. Does the patient have a contraindication to receiving Factor IX prophylaxis?
❒ Yes, *Continue to 12*
❒ No, *Continue to 12*

10. Does the patient have a current or a history of a life-threatening hemorrhage? ***ACTION REQUIRED***: If Yes, please attach chart notes documenting history of life-threatening hemorrhage(s).
❒ Yes, *Continue to 12*
❒ No, *Continue to 11*

11. Does the patient have a history of repeated, serious spontaneous bleeding episodes? ***ACTION REQUIRED***: If Yes, please attach chart notes documenting history of repeated, serious spontaneous bleeding episodes.
❒ Yes, *Continue to 12*
❒ No, *Continue to 12*

12. Does the patient have a negative adeno-associated virus serotype Rh74var (AAVRh74var) antibody test result? ***ACTION REQUIRED***: If Yes, please attach negative adeno-associated virus serotype Rh74var (AAVRh74var) antibody test result.
❒ Yes, *Continue to 13*
❒ No, *Continue to 13*

13. Does the patient have a hemoglobin count of greater than or equal to 11 g/dL at baseline? ***ACTION REQUIRED***: If Yes, please attach chart notes, lab tests documenting baseline hemoglobin count.
❒ Yes, *Continue to 14*
❒ No, *Continue to 14*

14. Does the patient have a platelet count of greater than or equal to 100,000 cells/microL at baseline? ***ACTION REQUIRED***: If Yes, please attach chart notes, lab tests documenting baseline platelet count results.
❒ Yes, *Continue to 15*
❒ No, *Continue to 15*

15. Does the patient have a creatinine of less than or equal to 2.0 mg/dL at baseline? ***ACTION REQUIRED***: If Yes, please attach chart notes, lab tests documenting baseline creatinine level.
❒ Yes, *Continue to 16*
❒ No, *Continue to 16*

16. Does the patient have alanine transaminase (ALT), aspartate aminotransferase (AST), and alkaline phosphatase (ALP) levels greater than 2 times the upper limit of normal (ULN) at baseline? ***ACTION REQUIRED***: If No, please attach chart notes, lab tests documenting baseline ALT, AST and ALP levels.
❒ Yes, *Continue to 17*
❒ No, *Continue to 17*

17. Does the patient have a bilirubin level greater than 1.5 times ULN (unless there is a diagnosis of Gilbert's Syndrome and the patient is otherwise stable) at baseline? ***ACTION REQUIRED***: If No, please attach chart notes, lab tests documenting baseline bilirubin level.
❒ Yes, *Continue to 18*
❒ No, *Continue to 18*

18. Does the patient have current unstable liver or biliary disease as defined by the presence of ascites, hepatic encephalopathy, coagulopathy, hypoalbuminemia, esophageal or gastric varices, persistent jaundice, or cirrhosis?
❒ Yes, *Continue to 19*
❒ No, *Continue to 19*

19. Has the patient undergone a hepatic ultrasound and/or elastography to rule out radiological liver abnormalities and/or sustained liver enzyme elevations?
❒ Yes, *Continue to 20*
❒ No, *Continue to 20*

20. Does the patient have cirrhosis or stage 3 or 4 liver fibrosis?
❒ Yes, *Continue to 21*
❒ No, *Continue to 21*

21. Does the patient have an active infection with hepatitis B virus or hepatitis C virus?
❒ Yes, *Continue to 22*
❒ No, *Continue to 22*

22. Is the patient currently receiving antiviral therapy for a prior hepatitis B virus or hepatitis C virus exposure?
❒ Yes, *Continue to 23*
❒ No, *Continue to 23*

23. Does the patient have uncontrolled human immunodeficiency virus (HIV) infection as defined as a CD4 cell count less than or equal to 200 mm^3 or viral load greater than 20 copies/mL?
❒ Yes, *Continue to 24*
❒ No, *Continue to 24*

24. Has the patient previously received the requested drug or any other gene therapy?
❒ Yes, *Continue to 25*
❒ No, *Continue to 25*

25. Will prophylactic use of Factor IX products be given after the requested drug administration once adequate Factor IX levels have been achieved (note: Factor IX therapy may be given in case of surgery, invasive procedures, trauma, or bleeds in the event that Beqvez-derived Factor IX activity is deemed insufficient for adequate hemostasis)?
❒ Yes, *Continue to 26*
❒ No, *Continue to 26*

26. Does the provider attest that liver enzymes and Factor IX activity will be followed per the protocol outlined in the prescribing information following receipt of the requested drug infusion?
❒ Yes, *No Further Questions*
❒ No, *No Further Questions*

I attest that this information is accurate and true, and that documentation supporting this information is available for review if requested by CVS Caremark or the benefit plan sponsor.

X_____
Prescriber or Authorized Signature **Date (mm/dd/yy)**

Send completed form to: Case Review Unit CVS Caremark Specialty Programs Fax: 1-855-330-1720

CVS Caremark Specialty Pharmacy ● 2211 Sanders Road NBT-6 ● Northbrook, IL 60062
Phone: 1-888-877-0518 ● Fax: 1-855-330-1720 ● www.caremark.com